Vistagen Therapeutics, Inc.
- Last sale
- Nov 12, 2026 · -5.85%
- Market cap
- $8.17M
- 46.19M shares
- Filings
- 913
Q2 2027+161.1% FY26 yoy
Q2 2027N/M FY26 yoy
Q2 2027N/M FY26 yoy
FY 2024derivedN/M FY24 yoy
Q2 2027N/M FY26 yoy
Q2 2027−54.1% FY26 yoy
- $8.17M
- —
- 3.4×
- 0.5×
- —
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2026 | 2026-03-31 | $1,269,000 | reported | |
| FY 2025 | 2025-03-31 | $486,000 | reported | |
| FY 2024 | 2024-03-31 | $1,064,000 | reported | |
| FY 2023 | 2023-03-31 | $227,000 | reported | |
| FY 2022 | 2022-03-31 | $1,109,000 | reported | |
| FY 2021 | 2021-03-31 | $1,089,500 | reported | |
| FY 2020 | 2020-03-31 | $0 | reported | |
| FY 2018 | 2018-03-31 | $0 | reported | |
| FY 2017 | 2017-03-31 | $1,250,000 | reported | |
| FY 2016 | 2016-03-31 | $0 | reported | |
| FY 2012 | 2013-03-31 | $200,400 | reported | |
| FY 2011 | 2012-03-31 | $1,342,200 | reported |
Pharmaceutical preparations
Vistagen Therapeutics, Inc. is the 209th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
ATXIAvenue Therapeutics, Inc.$1.4M—207.2%$988.5KNWBONorthwest Biotherapeutics Inc$1.4M0.3%4,365.9%$299.6MCPMDCannapharmarx, Inc.$1.4M66.1%817.2%$6.6M
VTGNVistagen Therapeutics, Inc. (this company)$1.3M161.1%5,491.3%$8.2M
NRXPNRX Pharmaceuticals, Inc.$1.2M—2,336.5%$97.8MLGVNLongeveron Inc.$1.2M49.9%1,893.6%$404.1KBLRXBioLineRx Ltd.$1.2M95.9%171.7%—NEUPNeuphoria Therapeutics Inc.$1.2M92.5%1,145.7%$14.0MSXTCChina SXT Pharmaceuticals, Inc.$1.1M34.6%545.2%$2.6MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR